Article Figures & Data
Figures
- FIGURE 1.
Structures of *I-SGMIB and 18F-SFB and scheme for labeling 5F7 Nanobody using 18F-RL-I.
- FIGURE 2.
Paired-label internalization of 125I-SGMIB-5F7 (blue bars) versus 18F-RL-I-5F7 (magenta bars) (A) and 125I-SGMIB-5F7 (blue bars) versus 18F-SFB-5F7 (green bars) (B) in BT-471M1 breast cancer cells in vitro. (C) Ratio of 18F to 125I obtained from 2 experiments.
- FIGURE 3.
18F-to-125I ratio in tumor from paired-label biodistribution of 18F-RL-I5F7 and 125I-SGMIB-5F7 and 18F-SFB-5F7 and 125I-SGMIB-5F7 in severe combined immunodeficiency mice bearing BT474M1 xenografts. Green bars = 18F-RL-I-5F7; magenta bars = 18F-SFB-5F7.
- FIGURE 4.
Tumor-to-tissue ratios for selected tissues obtained from biodistribution of 18F-RL-I-5F7 (A) and 18F-SFB-5F7 (B).
- FIGURE 5.
PET/CT images of mice bearing BT474M1 xenografts after injection of 18F-RL-I-5F7. Images were obtained at 1 and 2 h without and at 1 h with blocking of HER2 receptors by preadministration of trastuzumab.
Tables
- TABLE 1
Paired-Label Biodistribution of 18F-RL-I-5F7 and 125I-SGMIB-5F7 in Severe Combined Immunodeficiency Mice Bearing BT474M1 Xenografts
%ID/g* 1 h 2 h Tissue 125I-SGMIB 18F-RL-I-5F7 125I-SGMIB 18F-RL-I-5F7 Liver 3.27 ± 0.61 3.42 ± 0.57† 3.12 ± 0.94 3.17 ± 1.13† Spleen 2.01 ± 0.62 1.63 ± 0.51 1.85 ± 0.49 1.31 ± 0.40 Lung 10.47 ± 2.27 9.07 ± 1.06† 8.03 ± 0.83 6.63 ± 1.46† Heart 1.43 ± 0.47 1.30 ± 0.53† 0.62 ± 0.15 0.54 ± 0.14† Kidney 122.68 ± 18.03 139.45 ± 20.54 96.92 ± 30.55 105.02 ± 39.52† Stomach 1.91 ± 0.77 1.97 ± 0.78† 0.59 ± 0.28 0.54 ± 0.23† Small intestine 1.71 ± 0.52 2.10 ± 0.59 0.94 ± 0.30 1.28 ± 0.42 Large intestine 1.36 ± 0.31 1.68 ± 0.37 1.89 ± 1.30 2.47 ± 1.63 Muscle 1.16 ± 0.48 1.27 ± 0.50 0.91 ± 0.30 1.10 ± 0.38† Blood 1.75 ± 0.84 1.95 ± 0.87 0.65 ± 0.41 0.83 ± 0.43 Bone 0.76 ± 0.37 0.97 ± 0.31 0.78 ± 0.23 1.13 ± 0.28 Brain 0.10 ± 0.04 0.11 ± 0.04 0.07 ± 0.01 0.07 ± 0.02† Tumor 26.36 ± 3.12 28.97 ± 3.88 32.52 ± 12.11 36.28 ± 14.10 - TABLE 2
Paired Label Biodistribution of 18F-SFB-5F7 and 125I-SGMIB-5F7 in Severe Combined Immunodeficiency Mice Bearing BT474M1 Xenografts
%ID/g* 1 h 2 h Tissue 125I-SGMIB 18F-SFB 125I-SGMIB 18F-SFB Liver 2.02 ± 0.47 0.95 ± 0.21 2.18 ± 0.55 0.68 ± 0.13 Spleen 1.08 ± 0.33 0.67 ± 0.37 1.28 ± 0.22 0.52 ± 0.13 Lung 2.96 ± 0.39 2.31 ± 0.40 2.56 ± 0.70 2.00 ± 0.38† Heart 0.76 ± 0.20 0.62 ± 0.15 0.62 ± 0.13 0.54 ± 0.15† Kidney 102.50 ± 26.35 3.90 ± 1.13 93.00 ± 18.82 2.90 ± 0.77 Stomach 1.32 ± 1.17 1.43 ± 1.69† 1.98 ± 1.12 3.21 ± 4.62† Small intestine 1.17 ± 0.55 0.69 ± 0.33 1.32 ± 0.46 0.59 ± 0.19 Large intestine 1.18 ± 0.47 0.69 ± 0.50 3.86 ± 5.47 1.22 ± 1.66† Muscle 1.14 ± 0.27 1.16 ± 0.37† 1.21 ± 0.89 1.43 ± 1.20† Blood 0.96 ± 0.26 1.25 ± 0.29 0.67 ± 0.51 1.44 ± 0.88 Bone 0.88 ± 0.36 0.97 ± 0.55† 0.51 ± 0.09 0.54 ± 0.08† Brain 0.07 ± 0.02 0.09 ± 0.02 0.08 ± 0.05 0.12 ± 0.06 Tumor 27.88 ± 8.08 23.94 ± 7.00 33.59 ± 6.24 29.59 ± 5.10 - TABLE 3
Tumor SUV and %ID/g from Small-Animal PET/CT Imaging of Severe Combined Immunodeficiency Mice Bearing BT474M1 Xenografts after Injection of 18F-RL-I-5F7
1 h 2 h Mouse no. SUV %ID/g SUV %ID/g Unblocked 1* 4.2 ± 0.7 22.4 ± 3.8 4.3 ± 0.8 23.0 ± 4.2 2* 3.3 ± 0.4 17.8 ± 2.1 3.6 ± 0.7 19.4 ± 4.1 3† 4.9 ± 0.7 26.4 ± 3.9 4.9 ± 0.8 26.2 ± 4.2 4† 4.4 ± 0.6 24.9 ± 3.3 4.6 ± 0.7 26.1 ± 3.7 Blocked 1* 0.4 ± 0.1 2.1 ± 0.1 ND ND 2* 0.4 ± 0.1 2.1 ± 0.8 ND ND 3† 0.3 ± 0.1 1.3 ± 0.5 ND ND 4† 0.2 ± 0.1 1.0 ± 0.5 ND ND
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Single-Domain Antibody Theranostics on the Horizon
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer